Breaking News Instant updates and real-time market news.

VRTX

Vertex

$79.23

-1.33 (-1.65%)

06:41
10/17/16
10/17
06:41
10/17/16
06:41

Piper lays out reasons to buy Vertex with stock near 52-week lows

Piper Jaffray analyst Edward Tenthoff says shares of Vertex Pharmaceuticals are trading near 52-week lows following the company's "weak" Q3 guidance. The analyst believes investors should look past the outlook and he lays out six reasons for why to own the shares. The company will present Phase III ORKAMBI data on 58 homozygous F508del children aged 6-11 at the North American Cystic Fibrosis Conference being held from October 27-29, which formed the basis for label expansion, Tenthoff tells investors in a research note. Second, Vertex is launching ORKAMBI in homozygous F508del children, which should reaccelerate Q4 sales, the analyst contends. He also expects European reimbursement to come on-line in 2017, aiding revenue. The analyst sees revenue growth driving profitability and reiterates an Overweight rating on Vertex with a $129 price target. The stock closed Friday down $1.33 to $79.23.

  • 25

    Oct

  • 27

    Oct

  • 06

    Nov

VRTX Vertex
$79.23

-1.33 (-1.65%)

09/29/16
RBCM
09/29/16
NO CHANGE
RBCM
Vertex should be bought on weakness, says RBC Capital
After Vertex lowered its 2016 Orkambi revenue guidance, RBC Capital analyst Michael Yee says that the news "was not a surprise." The analyst remains upbeat on the company's triple CF treatment, and he recommends buying the stock on weakness. He keeps an Outperform rating on the shares.
09/29/16
JMPS
09/29/16
NO CHANGE
JMPS
Vertex Orkambi approval should drive growth, says JMP Securities
JMP Securities analyst Liisa Bayko says that FDA approval of Vertex's Orkambi in the 6-11 year old population should enable the company to grow in Q4 after a temporary slowdown in Q3. However, the analyst expects Q4 Orkambi sales to come in at $285M, versus the consensus outlook of $295M. She keeps a $103 price target and Outperform rating on the shares.
10/06/16
JMPS
10/06/16
NO CHANGE
JMPS
Vertex Orkambi checks positive, says JMP Securities
After conducting checks with doctors, JMP Securities analyst Liisa Bayko says that uptake of Vertex's Orkambi drug among 6-11 year old children appears to be "rapid." Bayko expects Orkambi's market share in the age range to reach 70% within six months. She reiterates a $103 price target and Outperform rating on the stock.
10/12/16
RBCM
10/12/16
NO CHANGE
RBCM
Outperform
Vertex competitor to report data soon, but has long way to go, says RBC Capital
RBC Capital analyst Michael Yee noted that Galapagos NV (GLPG) and partner AbbVie (ABBV) are likely to present new Phase IIa data for GLP-1837 for cystic fibrosis and host an analyst event on October 27, adding that he believes the data will likely be positive and suggest they are "on track" with progress on their triple pill. Yee adds it won't be surprising if Galapagos has positive '1837 "potentiator" data, as this is the easier of the components and only the first piece of a 3-pill drug. Vertex (VRTX) is also hosting an analyst event on Oct. 27 and will probably also give an update on its own "triple," said Yee, who thinks it should stay in the lead with most advanced triple. Yee keeps an Outperform rating on Vertex shares.

TODAY'S FREE FLY STORIES

ANTM

Anthem

$168.41

0.61 (0.36%)

, ESRX

Express Scripts

$67.25

0.79 (1.19%)

06:43
04/25/17
04/25
06:43
04/25/17
06:43
Recommendations
Anthem, Express Scripts analyst commentary  »

Citi sees Anthem trading…

ANTM

Anthem

$168.41

0.61 (0.36%)

ESRX

Express Scripts

$67.25

0.79 (1.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 18

    May

  • 06

    Jun

BBY

Best Buy

$51.15

0.51 (1.01%)

06:42
04/25/17
04/25
06:42
04/25/17
06:42
Upgrade
Best Buy rating change  »

Best Buy upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXE

Anixter

$80.70

1.35 (1.70%)

06:40
04/25/17
04/25
06:40
04/25/17
06:40
Hot Stocks
Anixter raises FY17 organic sales growth to 2%-5% »

The company said "We…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

ACN

Accenture

$119.36

0.13 (0.11%)

06:39
04/25/17
04/25
06:39
04/25/17
06:39
Hot Stocks
Accenture awarded $64M TSA contract »

Accenture Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXE

Anixter

$80.70

1.35 (1.70%)

06:38
04/25/17
04/25
06:38
04/25/17
06:38
Earnings
Anixter reports Q1 adjusted EPS $1.09, consensus 99c »

Reports Q1 revenue $1.9B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

AZZ

AZZ Inc.

$59.10

2.52 (4.45%)

06:37
04/25/17
04/25
06:37
04/25/17
06:37
Hot Stocks
AZZ Inc. awarded contract from Beijing Sino-American Yuli Power Technology »

AZZ Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FITB

Fifth Third

$25.33

0.71 (2.88%)

06:37
04/25/17
04/25
06:37
04/25/17
06:37
Earnings
Fifth Third reports Q1 EPS 38c, consensus 37c »

Reports Q1 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

MDT

Medtronic

$80.65

0.17 (0.21%)

06:37
04/25/17
04/25
06:37
04/25/17
06:37
Hot Stocks
Medtronic says DCB demonstrates consistent results »

Medtronic reinforced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 06

    Jun

PHM

PulteGroup

$23.08

-0.24 (-1.03%)

06:35
04/25/17
04/25
06:35
04/25/17
06:35
Hot Stocks
PulteGroup reports backlog of 9,323 homes at Q1-end »

For the quarter, net new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

  • 09

    May

  • 10

    May

  • 11

    May

  • 12

    May

GPK

Graphic Packaging

$13.58

0.04 (0.30%)

06:35
04/25/17
04/25
06:35
04/25/17
06:35
Earnings
Graphic Packaging reports Q1 EPS 14c, consensus 12c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 24

    May

EPZM

Epizyme

$14.90

0.35 (2.41%)

06:34
04/25/17
04/25
06:34
04/25/17
06:34
Hot Stocks
FDA grants Fast Track designation to Epizyme's tazemetostat »

Epizyme announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIT

CIT Group

$44.29

0.69 (1.58%)

06:34
04/25/17
04/25
06:34
04/25/17
06:34
Earnings
CIT Group reports Q1 EPS ex-items 80c, consensus 59c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

PHM

PulteGroup

$23.08

-0.24 (-1.03%)

06:34
04/25/17
04/25
06:34
04/25/17
06:34
Hot Stocks
PulteGroup reports Q1 value of net new orders up 16% to $2.4B »

Net New Orders Up 8% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

  • 09

    May

  • 10

    May

  • 11

    May

  • 12

    May

BA

Boeing

$182.06

1.68 (0.93%)

, EADSY

Airbus

$20.02

0.84 (4.38%)

06:33
04/25/17
04/25
06:33
04/25/17
06:33
Periodicals
Boeing nears decision on 737-10 jet launch, Reuters reports »

Boeing (BA) is close to a…

BA

Boeing

$182.06

1.68 (0.93%)

EADSY

Airbus

$20.02

0.84 (4.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 31

    May

PHM

PulteGroup

$23.08

-0.24 (-1.03%)

06:33
04/25/17
04/25
06:33
04/25/17
06:33
Earnings
PulteGroup reports Q1 EPS 28c, consensus 29c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

  • 09

    May

  • 10

    May

  • 11

    May

  • 12

    May

SVU

Supervalu

$3.85

0.01 (0.26%)

06:32
04/25/17
04/25
06:32
04/25/17
06:32
Hot Stocks
Supervalu reports Q4 retail identical store sales down 5.8% »

Total net sales within…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

NLSN

Nielsen

$41.59

0.59 (1.44%)

06:32
04/25/17
04/25
06:32
04/25/17
06:32
Earnings
Nielsen sees FY17 GAAP EPS $1.40-$1.46 , consensus $2.68 »

Sees FY17 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 27

    Apr

  • 03

    May

  • 31

    May

FBC

Flagstar Bancorp

$28.69

0.31 (1.09%)

06:32
04/25/17
04/25
06:32
04/25/17
06:32
Earnings
Flagstar Bancorp reports Q1 EPS 46c, consensus 38c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

  • 23

    May

NLSN

Nielsen

$41.59

0.59 (1.44%)

06:31
04/25/17
04/25
06:31
04/25/17
06:31
Earnings
Nielsen reports Q1 EPS 20c, consensus 48c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 27

    Apr

  • 03

    May

  • 31

    May

SVU

Supervalu

$3.85

0.01 (0.26%)

06:31
04/25/17
04/25
06:31
04/25/17
06:31
Earnings
Supervalu reports Q4 adjusted EPS 13c, consensus 9c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

BHI

Baker Hughes

$58.65

0.97 (1.68%)

06:30
04/25/17
04/25
06:30
04/25/17
06:30
Earnings
Baker Hughes reports Q1 adjusted EPS (4c), consensus (21c) »

Reports Q1 revenue $2.3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

LLY

Eli Lilly

$83.42

1.53 (1.87%)

06:29
04/25/17
04/25
06:29
04/25/17
06:29
Hot Stocks
Eli Lilly backs FY17 EPS view of $4.05-$4.15, consensus $4.11 »

Backs FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

  • 07

    May

  • 31

    May

WHR

Whirlpool

$174.80

3.29 (1.92%)

06:28
04/25/17
04/25
06:28
04/25/17
06:28
Hot Stocks
Whirlpool sees about $300M of raw material inflation in 2017 »

Says had sort-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

CAPR

Capricor Therapeutics

$3.09

0.08 (2.66%)

06:28
04/25/17
04/25
06:28
04/25/17
06:28
Conference/Events
Capricor Therapeutics to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 27

    Apr

LLY

Eli Lilly

$83.42

1.53 (1.87%)

06:27
04/25/17
04/25
06:27
04/25/17
06:27
Earnings
Eli Lilly reports Q1 EPS 98c, consensus 96c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

  • 07

    May

  • 31

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.